The Semaglutide Market continues to expand rapidly, valued at USD 29.14 billion in 2024 and projected to reach USD 81.08 billion by 2034, growing at a CAGR of 10.8%. Increasing prevalence of type 2 diabetes, obesity, and cardiometabolic disorders, combined with the emergence of new oral and combination therapies, are driving market growth. Pharmaceutical companies...